Study identifier:D2453C00045
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Effects of candesartan cilexetil (candesartan) on diabetic retinopathy in type 1 diabetic patients without retinopathy.
Type 1 Diabetes
Phase 3
No
candesartan cilexetil
All
5238
Interventional
18 Years - 50 Years
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Oct 2013 by AstraZeneca
AstraZeneca
Takeda
No locations available
Arms | Assigned Interventions |
---|---|
No Intervention: 1 Placebo | - |
Experimental: 2 candesartan cilexetil | Drug: candesartan cilexetil 32 mg once daily oral tablet given over 60 months Other Name: ATACAND |